Amylin liver nonalcoholic steatohepatitis diet-induced obese-MASH mice with biopsy-confirmed MASH and fibrosis were administered (subcutaneous [SC], daily [QD]) vehicle, zalfermin (0.05 or 0.2 mg/kg), semaglutide (3 or 120 μg/kg), or zalfermin 0.05 mg/kg + semaglutide 3 μg/kg for 8 weeks (n = 11–12 per group). Here, IAPP is linked to metabolic dysfunction-associated steatohepatitis.